Bath & Body Works Inc vs Charles River Laboratories Intl. Inc — how do they compare? Bath & Body Works Inc trades at $19.4 (market cap $4.04B), while Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.8× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 3.99% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BBWI | CRL | |
|---|---|---|
Market Cap | $4.04B | $11.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.11 | $233.60 |
52-Week Low | $14.85 | $145.57 |
Enterprise Value | $7.93B | $14.00B |
Dividend Yield | 3.99% | — |
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $20.42, up 0.44% today, with a bearish technical signal but attractive valuation metrics including a P/E of 5.8 and P/S of 0.58. Recent earnings show mixed quarterly beats, with Q1 2026 exceeding expectations. The company maintains solid profitability with a 10.03% net income margin and positive cash flow trends projected for 2026. Strategic initiatives include a new Ulta Beauty partnership and international expansion to drive growth amid declining revenue trends.
Outlook: BBWI presents a value opportunity with deep valuation discounts and operational strengths, though persistent revenue declines and high debt pose risks. Analyst consensus is cautiously optimistic with a $22 price target, suggesting modest upside potential if turnaround efforts gain traction against competitive and macroeconomic headwinds.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Trailing returns across standard periods
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →